Novo Nordisk is also expanding its CVM pipeline. In October2023, the company announced it was acquiring ocedurenonefor uncontrolled hypertension, with potential application incardiovascular and kidney disease, from KBP Biosciences forup to $1.3bn. Ocedurenone is an orally administered, smallmolecule, non-steroidal mineralocorticoid receptor antagonistthat is being tested in the Phase III CLARION-CKD trial inpatients with uncontrolled hypertension and advanced chronickidney disease.
关注微信
